VivoSeq
Cardiovascular

Cardiometabolic Disease

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Cardiometabolic Disease is an early-stage landscape with 2 programs across 3 companies. The most active players are Amgen, Novo Nordisk, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Novo Nordisk logo

Novo Nordisk

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Amg 513

Amgen

NNC6022-0001

Novo Nordisk

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Not yet recruiting1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT06336005·56 enrolled
Qatar Cardiometabolic Cohort (QCMC)
Not yet recruiting·WWeill Cornell Medical College in Qatar·N/A·NCT07675928·3,000 enrolled
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
Recruiting·Amgen logoAmgen·Phase 1·NCT06585462·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)